BNP Paribas Asset Management
RCUS icon

BNP Paribas Asset Management’s Arcus Biosciences RCUS Stock Holding History

BNP Paribas Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.7M Sell
1,654,754
-32,620
-2% -$704K 0.04% 405
2025
Q4 		$40.2M Buy
1,687,374
+267,389
+19% +$5.46M 0.05% 355
2025
Q3 		$19.3M Buy
1,419,985
+24,259
+2% +$252K 0.05% 357
2025
Q2 		$11.4M Sell
1,395,726
-232,293
-14% -$1.98M 0.03% 433
2025
Q1 		$12.8M Buy
1,628,019
+106,235
+7% +$1.23M 0.03% 407
2024
Q4 		$22.7M Buy
1,521,784
+590,736
+63% +$9.65M 0.06% 310
2024
Q3 		$14.2M Buy
931,048
+186,750
+25% +$2.94M 0.04% 374
2024
Q2 		$11.3M Buy
744,298
+59,273
+9% +$957K 0.03% 404
2024
Q1 		$12.9M Buy
685,025
+145,298
+27% +$2.51M 0.03% 390
2023
Q4 		$10.3M Buy
539,727
+22,863
+4% +$365K 0.03% 417
2023
Q3 		$9.28M Sell
516,864
-94,308
-15% -$1.89M 0.03% 419
2023
Q2 		$12.4M Sell
611,172
-163,620
-21% -$3.12M 0.04% 364
2023
Q1 		$14.1M Buy
774,792
+9,242
+1% +$177K 0.05% 362
2022
Q4 		$15.8M Buy
765,550
+142,986
+23% +$3.93M 0.06% 348
2022
Q3 		$16.3M Buy
622,564
+63,962
+11% +$1.69M 0.06% 323
2022
Q2 		$14.2M Sell
558,602
-238,489
-30% -$5.84M 0.05% 341
2022
Q1 		$25.2M Sell
797,091
-64,203
-7% -$2.15M 0.09% 267
2021
Q4 		$34.9M Buy
861,294
+76,188
+10% +$2.96M 0.12% 211
2021
Q3 		$27.4M Buy
785,106
+473,310
+152% +$14.7M 0.1% 234
2021
Q2 		$8.56M Buy
+311,796
New +$8.91M 0.03% 460

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BNP Paribas Asset Management's RCUS Position: Q1 2026 in Review

BNP Paribas Asset Management reduced its Arcus Biosciences (RCUS) stake by 1.9% in Q1 2026, selling an estimated $704K and leaving 1,654,754 shares worth $35.7M. The position accounts for 0.04% of the portfolio, ranked #405.

BNP Paribas Asset Management first reported a position in RCUS in Q2 2021 and has held it in 20 quarters since. The position peaked at $40.2M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • BNP Paribas Asset Management held 1,654,754 shares of Arcus Biosciences worth $35.7M as of Q1 2026.
  • BNP Paribas Asset Management sold 32,620 Arcus Biosciences shares in Q1 2026, an estimated $704K.
  • Arcus Biosciences made up 0.04% of BNP Paribas Asset Management's portfolio in Q1 2026, its #405 holding.
  • BNP Paribas Asset Management first reported a position in Arcus Biosciences in Q2 2021 and has held it in 20 quarters since.
  • BNP Paribas Asset Management's Arcus Biosciences position peaked at $40.2M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.